Latest Pharma Insights
Insilico’s CEO On AI, Drug Novelty And Beating China Biotech At R&D
CEO Alex Zhavoronkov talks about the firm’s progress in AI-driven R&D, hitting the right level of drug novelty, partnering with Eli Lilly and its goal of outperforming China’s biopharma engine.
Scrip - March 24, 2026
CEO Alex Zhavoronkov talks about the firm’s progress in AI-driven R&D, hitting the right level of drug novelty, partnering with Eli Lilly and its goal of outperforming China’s biopharma engine.
Scrip - March 24, 2026
Cambrex Targets Complex APIs As Outsourcing Demand Rises
Cambrex is accelerating API capacity expansion across the US and Europe, advancing a $120m Iowa project and a $30m Milan upgrade as it builds scale in complex chemistries, peptides and high-potency manufacturing amid rising reshoring demand.
Generics Bulletin - March 24, 2026
Cambrex is accelerating API capacity expansion across the US and Europe, advancing a $120m Iowa project and a $30m Milan upgrade as it builds scale in complex chemistries, peptides and high-potency manufacturing amid rising reshoring demand.
Generics Bulletin - March 24, 2026
Hatch-Waxman Needs Repair To Fight Against Serial Patent Litigations
Serial patent litigations have become a loophole in the Hatch-Waxman Act, disbalancing the scale of innovation and competition, said Jon Potter, executive director of the newly established Coalition Against Pharma Patent Abuse, in an exclusive Generics Bulletin interview.
Generics Bulletin - March 24, 2026
Serial patent litigations have become a loophole in the Hatch-Waxman Act, disbalancing the scale of innovation and competition, said Jon Potter, executive director of the newly established Coalition Against Pharma Patent Abuse, in an exclusive Generics Bulletin interview.
Generics Bulletin - March 24, 2026
Abbott Completes $21B Exact Sciences Deal To Expand Cancer Diagnostics
Abbott said Exact Sciences will operate as a subsidiary following the transaction. The acquisition adds a business generating more than $3bn in annual revenue to Abbott’s diagnostics portfolio.
Medtech Insight - March 24, 2026
Abbott said Exact Sciences will operate as a subsidiary following the transaction. The acquisition adds a business generating more than $3bn in annual revenue to Abbott’s diagnostics portfolio.
Medtech Insight - March 24, 2026
Indian Medical Device Makers Seek Duty Relief As Gulf Shipping Disruptions Hit Input Costs
Rising logistics and energy costs linked to disruptions in shipping through the Strait of Hormuz are beginning to ripple through India’s medical device supply chain. Industry leaders warn prolonged instability could raise production costs, strain working capital and disrupt manufacturing schedules.
Medtech Insight - March 24, 2026
Rising logistics and energy costs linked to disruptions in shipping through the Strait of Hormuz are beginning to ripple through India’s medical device supply chain. Industry leaders warn prolonged instability could raise production costs, strain working capital and disrupt manufacturing schedules.
Medtech Insight - March 24, 2026
India Deal Strengthens Bio-Thera’s Global Golimumab Strategy
Bio-Thera has added India to its BAT2506 partnership with Intas, granting exclusive commercialization rights and expanding a global network spanning the US and Canada, as the firm builds its presence in the emerging golimumab biosimilars market.
Generics Bulletin - March 24, 2026
Bio-Thera has added India to its BAT2506 partnership with Intas, granting exclusive commercialization rights and expanding a global network spanning the US and Canada, as the firm builds its presence in the emerging golimumab biosimilars market.
Generics Bulletin - March 24, 2026
Biomedical Engineering of ADCs: Precision Oncology by Design
Uncover how synthetic biology, biomarkers, and GenAI are advancing ADCs - and why CROs are essential to clinical and regulatory success.
Scrip - March 24, 2026
Uncover how synthetic biology, biomarkers, and GenAI are advancing ADCs - and why CROs are essential to clinical and regulatory success.
Scrip - March 24, 2026
Gilead Hands Galapagos A Rebuild Opportunity With Ouro Buyout
The deal, which could be worth over $2bn, looks to bolster Gilead's growing immunology franchise while also granting long-time partner Galapagos a chance at a future royalty stream.
Scrip - March 24, 2026
The deal, which could be worth over $2bn, looks to bolster Gilead's growing immunology franchise while also granting long-time partner Galapagos a chance at a future royalty stream.
Scrip - March 24, 2026
UBE Deal Helps Kyorin On Road To In-Licensing Target
Kyorin signs in-licensing agreement with UBE to grow its new drug pipeline as it chases mid-term deal target.
Scrip - March 24, 2026
Kyorin signs in-licensing agreement with UBE to grow its new drug pipeline as it chases mid-term deal target.
Scrip - March 24, 2026
US TikTok Shop Fragrance Sales Surge As Creators Reshape Gen Alpha’s Usage Of Scent
Fragrance intelligence and analytics provider OnScent says US TikTok Shop is on its way to achieving annual sales of $500m.
HBW Insight - March 24, 2026
Fragrance intelligence and analytics provider OnScent says US TikTok Shop is on its way to achieving annual sales of $500m.
HBW Insight - March 24, 2026
Insilico’s CEO On AI, Drug Novelty And Beating China Biotech At R&D
CEO Alex Zhavoronkov talks about the firm’s progress in AI-driven R&D, hitting the right level of drug novelty, partnering with Eli Lilly and its goal of outperforming China’s biopharma engine.
Scrip - March 24, 2026
CEO Alex Zhavoronkov talks about the firm’s progress in AI-driven R&D, hitting the right level of drug novelty, partnering with Eli Lilly and its goal of outperforming China’s biopharma engine.
Scrip - March 24, 2026
Biomedical Engineering of ADCs: Precision Oncology by Design
Uncover how synthetic biology, biomarkers, and GenAI are advancing ADCs - and why CROs are essential to clinical and regulatory success.
Scrip - March 24, 2026
Uncover how synthetic biology, biomarkers, and GenAI are advancing ADCs - and why CROs are essential to clinical and regulatory success.
Scrip - March 24, 2026
Gilead Hands Galapagos A Rebuild Opportunity With Ouro Buyout
The deal, which could be worth over $2bn, looks to bolster Gilead's growing immunology franchise while also granting long-time partner Galapagos a chance at a future royalty stream.
Scrip - March 24, 2026
The deal, which could be worth over $2bn, looks to bolster Gilead's growing immunology franchise while also granting long-time partner Galapagos a chance at a future royalty stream.
Scrip - March 24, 2026
UBE Deal Helps Kyorin On Road To In-Licensing Target
Kyorin signs in-licensing agreement with UBE to grow its new drug pipeline as it chases mid-term deal target.
Scrip - March 24, 2026
Kyorin signs in-licensing agreement with UBE to grow its new drug pipeline as it chases mid-term deal target.
Scrip - March 24, 2026
Abbott Completes $21B Exact Sciences Deal To Expand Cancer Diagnostics
Abbott said Exact Sciences will operate as a subsidiary following the transaction. The acquisition adds a business generating more than $3bn in annual revenue to Abbott’s diagnostics portfolio.
Medtech Insight - March 24, 2026
Abbott said Exact Sciences will operate as a subsidiary following the transaction. The acquisition adds a business generating more than $3bn in annual revenue to Abbott’s diagnostics portfolio.
Medtech Insight - March 24, 2026
Indian Medical Device Makers Seek Duty Relief As Gulf Shipping Disruptions Hit Input Costs
Rising logistics and energy costs linked to disruptions in shipping through the Strait of Hormuz are beginning to ripple through India’s medical device supply chain. Industry leaders warn prolonged instability could raise production costs, strain working capital and disrupt manufacturing schedules.
Medtech Insight - March 24, 2026
Rising logistics and energy costs linked to disruptions in shipping through the Strait of Hormuz are beginning to ripple through India’s medical device supply chain. Industry leaders warn prolonged instability could raise production costs, strain working capital and disrupt manufacturing schedules.
Medtech Insight - March 24, 2026
US TikTok Shop Fragrance Sales Surge As Creators Reshape Gen Alpha’s Usage Of Scent
Fragrance intelligence and analytics provider OnScent says US TikTok Shop is on its way to achieving annual sales of $500m.
HBW Insight - March 24, 2026
Fragrance intelligence and analytics provider OnScent says US TikTok Shop is on its way to achieving annual sales of $500m.
HBW Insight - March 24, 2026
Cambrex Targets Complex APIs As Outsourcing Demand Rises
Cambrex is accelerating API capacity expansion across the US and Europe, advancing a $120m Iowa project and a $30m Milan upgrade as it builds scale in complex chemistries, peptides and high-potency manufacturing amid rising reshoring demand.
Generics Bulletin - March 24, 2026
Cambrex is accelerating API capacity expansion across the US and Europe, advancing a $120m Iowa project and a $30m Milan upgrade as it builds scale in complex chemistries, peptides and high-potency manufacturing amid rising reshoring demand.
Generics Bulletin - March 24, 2026
Hatch-Waxman Needs Repair To Fight Against Serial Patent Litigations
Serial patent litigations have become a loophole in the Hatch-Waxman Act, disbalancing the scale of innovation and competition, said Jon Potter, executive director of the newly established Coalition Against Pharma Patent Abuse, in an exclusive Generics Bulletin interview.
Generics Bulletin - March 24, 2026
Serial patent litigations have become a loophole in the Hatch-Waxman Act, disbalancing the scale of innovation and competition, said Jon Potter, executive director of the newly established Coalition Against Pharma Patent Abuse, in an exclusive Generics Bulletin interview.
Generics Bulletin - March 24, 2026
India Deal Strengthens Bio-Thera’s Global Golimumab Strategy
Bio-Thera has added India to its BAT2506 partnership with Intas, granting exclusive commercialization rights and expanding a global network spanning the US and Canada, as the firm builds its presence in the emerging golimumab biosimilars market.
Generics Bulletin - March 24, 2026
Bio-Thera has added India to its BAT2506 partnership with Intas, granting exclusive commercialization rights and expanding a global network spanning the US and Canada, as the firm builds its presence in the emerging golimumab biosimilars market.
Generics Bulletin - March 24, 2026
Oncology’s Next Decade: The Therapies And Players Reshaping A $400bn Future
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
In Vivo - March 23, 2026
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
In Vivo - March 23, 2026
Practicalities For AI-Enabled Devices As Digital (R)evolution Picks Up Pace
AI-enabled tools deliver faster radiology reads, clinical decision-support, personalized treatment insights and continuous patient monitoring, but a new report from Firefinch Software and IMed Consultancy advises device developers how to enter and stay in this rapidly growing market.
In Vivo - March 23, 2026
AI-enabled tools deliver faster radiology reads, clinical decision-support, personalized treatment insights and continuous patient monitoring, but a new report from Firefinch Software and IMed Consultancy advises device developers how to enter and stay in this rapidly growing market.
In Vivo - March 23, 2026
Chugai’s Narrow Partnering Strategy Means Less Competition
Chugai’s partnering office in South San Francisco advances the Japanese company’s business development activities in the US beyond its venture fund established in Boston in 2023.
In Vivo - March 23, 2026
Chugai’s partnering office in South San Francisco advances the Japanese company’s business development activities in the US beyond its venture fund established in Boston in 2023.
In Vivo - March 23, 2026